THE PHAGE, Inc.

Cover Block

Open sources

Field	Value
Name	THE PHAGE, Inc.
Tagline	A Japanese medical device company developing AI technology to predict postprandial blood glucose levels [Crunchbase]
Headquarters	Shibuya, Japan [PR Times, October 2026]
Founded	2021 [PR Times, October 2026]
Stage	Series A [PR Times, October 2026]
Business Model	B2B
Industry	Healthtech
Technology	AI / Machine Learning
Geography	East Asia
Growth Profile	Venture Scale
Funding Label	Series A [PR Times, October 2026]
Total Disclosed	¥570 million [PR Times, October 2026]

Links

PUBLIC

• Website: https://thephage.life/
• X / Twitter: https://x.com/TOKUNAGA_Shohei
• Google Play: https://play.google.com/store/apps/details?id=life.thephage.app

What an Investor Needs First

PUBLIC THE PHAGE, Inc. is building an AI-driven blood glucose management platform centered on predicting postprandial glucose levels, and it merits attention now because the company has just disclosed a ¥570 million Series A first close led by Itochu Technology Ventures, a meaningful financing signal in a category where clinical usefulness and distribution both matter [PR Times, October 2026] [Crunchbase] [Tracxn]. Public records place the company in Shibuya and show it was founded in 2021, with CEO Shohei Tokunaga serving as representative director, which gives investors a clear legal and operating anchor even though the broader founding story remains only lightly documented in public sources [PR Times, October 2026] [Crunchbase].

The product thesis is relatively specific: THE PHAGE says it develops AI to predict postprandial blood glucose levels, while third-party databases describe the company as offering an AI-based blood glucose monitoring platform; Genesia Ventures adds that its Glucose Flight® system is positioned as a personalized diabetes support tool that analyzes biometric data and generates lifestyle or treatment recommendations [thephage.life, 2026] [Crunchbase] [Tracxn] [Genesia Ventures]. That combination suggests the differentiation may rest less on generic tracking and more on meal-level prediction and recommendation, although the current public record does not yet establish clinical performance, payer adoption, or customer concentration [Genesia Ventures] [Dealroom.co].

On team quality, the verified evidence is narrower than investors would usually want at this stage, but it is directionally constructive. Tokunaga is named publicly as CEO, and Hidetora Kawakami, a professor at Chiba University Graduate School of Medicine, is identified in public investor materials as involved with the company and participating as Chief Scientific Officer, which indicates a scientific advisory layer relevant to a diabetes-focused product [PR Times, October 2026] [FIRST CVC].

The financing picture is clearer than the operating picture. PR Times reports the October 2026 Series A first round at ¥570 million, with participation from Tokio Marine & Nichido Fire Insurance, Fukui Capital Partners, Genesia Ventures, and Vision Incubate, while the structured company profile points to a B2B business model rather than a consumer app strategy alone [PR Times, October 2026].

Over the next 12 to 18 months, the key questions are straightforward: whether THE PHAGE can convert its prediction engine into repeatable enterprise distribution, whether Glucose Flight® can show evidence of sustained engagement or clinical utility in type 2 diabetes workflows, and whether partnerships such as the reported work with Meiji and food databases translate into measurable product advantage rather than simply better data inputs [Dealroom.co] [Google Play]. Those are the milestones that will determine whether this is primarily an interesting applied-AI healthtech company or the early shape of a defensible metabolic health platform.

Partially corroborated -- Core company identity, headquarters, founding year, CEO, and Series A round are corroborated by PR Times and Crunchbase, but product scope and scientific-team details rely in part on company, investor, and database sources with limited independent validation.

Taxonomy Snapshot

Axis	Value
Stage	Series A
Business Model	B2B
Industry / Vertical	Healthtech
Technology Type	AI / Machine Learning
Geography	East Asia
Growth Profile	Venture Scale
Funding	Series A

Inside the Company

PUBLIC

THE PHAGE, Inc. presents as an early-stage Japanese healthtech company focused on a fairly specific clinical problem: predicting postprandial, or after-meal, blood glucose levels with AI [Crunchbase]. Public records place the company in Shibuya, Japan, and list its founding in 2021, which matters here because the business is still best understood as a recent venture building around a defined metabolic-health use case rather than a mature device platform with long operating history [Crunchbase]. The company website describes the same core focus, developing AI for postprandial blood glucose prediction, which provides a useful cross-check on category and product intent even if commercial details remain limited in public materials [thephage.life, 2026].

The visible chronology is short but coherent. Crunchbase lists the company as founded in 2021 [Crunchbase], and the company website frames the business around food-related blood glucose prediction and management under the THE PHAGE name [thephage.life, 2026]. The clearest dated milestone in the public record is an October 2026 financing announcement, but the round mechanics sit outside this section's source constraints; for overview purposes, the key point is that the company has remained active from its 2021 formation into 2026 with a consistent product thesis centered on glucose prediction [thephage.life, 2026].

Partially corroborated -- Confirmed in part by Crunchbase and the company website; chronology beyond founding and current focus is only partially supported within the allowed source set.

Under the Hood

MIXED

The public record is narrow, but it is consistent on the core product claim: THE PHAGE is building software that predicts postprandial, or after-meal, blood glucose levels, with diabetes management as the practical use case [Crunchbase] [Tracxn] [thephage.life, 2026]. That matters because the company is not presenting itself as a general wellness app. Across public profiles and investor materials, the product is framed as an AI-based blood glucose management platform, most often under the name Glucose Flight®, with personalized lifestyle guidance and treatment support tied to individual biometric data [Tracxn] [Genesia Ventures] [Dealroom.co].

The evidence suggests a decision-support layer rather than a hardware-first device thesis. Genesia Ventures describes Glucose Flight® as a comprehensive diabetes treatment support system that analyzes individual biometric data and proposes optimized treatment indices, while Dealroom says the service evaluates meals based on blood sugar fluctuations to aid diabetes management [Genesia Ventures] [Dealroom.co]. A company post also says the firm collaborates with Meiji and uses large food databases to improve model accuracy, which, if accurate, would point to a data-advantaged nutrition input rather than glucose prediction from sensor data alone [Dealroom.co]. Public materials do not establish whether the current product is sold primarily to providers, employers, insurers, or other enterprise buyers, and they do not verify a proprietary hardware component [PR Times, October 2026] [Crunchbase].

The technical stack is only partly visible from public sources, so the safest read is that the differentiation rests on applied machine learning and domain-specific data, not on a disclosed foundation model or novel device architecture [thephage.life, 2026] [Crunchbase]. The website describes the company plainly as a developer of AI for postprandial glucose prediction, and external profiles repeat that claim with modest variation [thephage.life, 2026] [Crunchbase] [Tracxn]. Public evidence also links Hidetora Kawakami of Chiba University Graduate School of Medicine to the company in a scientific leadership role, which lends some credibility to the clinical framing, although the sources used here do not verify published validation data, regulatory status, or performance benchmarks against standard diabetes management workflows [FIRST CVC] [ResearchGate].

Partially corroborated -- Product positioning is corroborated across Crunchbase, Tracxn, the company website, and investor materials, but important details on technical performance, deployment model, and validation remain only partially substantiated by public sources.

Market Research

PUBLIC

The market matters now because postprandial glucose management sits at the intersection of two durable healthcare priorities, diabetes prevalence and earlier intervention, but the public record for THE PHAGE is still too thin to support a company-specific market model without importing unsupported assumptions [Crunchbase] [PR Times, October 2026].

On addressable market sizing, the evidence base here is narrow. None of the provided third-party materials supply a named TAM, SAM, or SOM for AI-driven postprandial glucose prediction, and the company announcement itself does not offer one [PR Times, October 2026]. The most defensible read is therefore qualitative: THE PHAGE appears to target a subset of the broader diabetes management and digital therapeutics workflow, specifically tools that use biometric and meal-related data to predict blood glucose responses and support individualized recommendations [Genesia Ventures] [Dealroom.co] [thephage.life, 2026].

That framing matters because it places the company in an adjacent market cluster rather than a single clean category. Public descriptions point to a product called Glucose Flight®, characterized as a diabetes treatment support system and a service that evaluates meals based on blood sugar fluctuations, with personalized lifestyle recommendations layered on top [Genesia Ventures] [Dealroom.co]. Tracxn separately describes THE PHAGE as an AI-based blood glucose monitoring platform, which suggests overlap with remote monitoring software, metabolic health applications, and broader clinical decision support tooling rather than a standalone device market [Tracxn].

The demand drivers that are visible in the sources are practical rather than speculative. If a product can forecast postprandial glucose responses with enough accuracy to change diet or treatment behavior, it addresses a recognized management problem in type 2 diabetes and related metabolic conditions, where meal-by-meal variability is difficult for patients and clinicians to interpret in real time [Google Play] [Genesia Ventures]. The company and investor materials also point to use of biometric inputs and food databases, including a reported collaboration with Meiji, which implies an effort to make recommendations more personalized and more usable in daily care settings [Dealroom.co].

Market lens	Publicly supported read	Source
Core category	AI-based blood glucose monitoring and prediction platform	[Tracxn]
Clinical use case	Postprandial blood glucose prediction and management	[Crunchbase] [thephage.life, 2026]
Product adjacency	Diabetes treatment support system with lifestyle recommendations	[Genesia Ventures]
Workflow adjacency	Meal evaluation based on blood sugar fluctuations	[Dealroom.co]

The table points to a category with several overlapping entry points, which cuts both ways. It expands the surface area for adoption, but it also means the real market definition will depend on who pays, provider, employer, insurer, or patient, and the public materials do not resolve that yet [PR Times, October 2026] [Crunchbase].

Adjacent and substitute markets are easier to identify than direct market size. On the adjacent side, THE PHAGE appears closest to digital diabetes management, nutrition-linked metabolic health software, and AI-supported treatment optimization [Genesia Ventures] [Tracxn]. On the substitute side, any incumbent workflow that helps patients understand glucose responses, including conventional diabetes education, general-purpose glucose logging apps, and broader monitoring platforms, could compete for budget or clinician attention even if the technical approach differs [Google Play] [Dealroom.co].

The regulatory and macro picture is relevant, even if the sources stop short of giving product-specific approvals or reimbursement status. The company is described as a Japanese medical device company, which implies a higher evidentiary bar than a consumer wellness app and suggests that commercialization may be influenced by clinical validation, medical device oversight, and integration into existing care pathways in Japan [PR Times, October 2026]. A clinical trial registry entry in UMIN-CTR also indicates at least some connection to formal clinical research activity, though the provided material does not establish outcomes, endpoints, or commercial impact [umin.ac.jp].

A second macro force is capital formation. The October 2026 Series A first round, totaling ¥570 million and led by Itochu Technology Ventures, with participation from insurers and repeat backers, signals that investors see enough category formation in AI-enabled metabolic care to underwrite continued product development [PR Times, October 2026]. That does not validate end-market demand by itself, but it does suggest that the company is operating in a segment investors believe can support venture-scale growth if clinical and distribution hurdles are cleared [PR Times, October 2026] [Genesia Ventures].

Partially corroborated -- This section relies on one independent database description and several company or investor-adjacent sources, with no third-party market sizing report in the provided materials.

Competition and Substitutes

Competitive Positioning

MIXED THE PHAGE appears to sit in a narrower lane than broad diabetes platforms, with the public record pointing to an AI-led postprandial glucose prediction and management product rather than a full-stack continuous glucose monitoring or insulin delivery offering [Crunchbase] [Tracxn] [Genesia Ventures].

The immediate competitive map is therefore best read by segment, not by a single peer set. At one end are diabetes device and software incumbents that manage glucose data at scale, including app layers tied to sensors, care programs, or treatment workflows. In the middle are specialist software challengers focused on glycemic insight, meal response, or behavior guidance. Adjacent substitutes include nutrition and wellness applications that promise meal scoring or lifestyle coaching without positioning themselves as regulated diabetes support. Public sources do not name direct head-to-head competitors for THE PHAGE, which limits precision, but they do consistently place the company around postprandial prediction, blood glucose monitoring support, and its Glucose Flight product line rather than hardware ownership [Crunchbase] [Tracxn] [Dealroom.co] [Genesia Ventures].

Where the company seems to have an edge today is in product specificity and data context, although both advantages look early and somewhat perishable. Multiple sources describe a focus on predicting postprandial blood glucose levels and translating biometric inputs into individualized recommendations, which is narrower than generic logging or coaching applications [Crunchbase] [Genesia Ventures] [thephage.life, 2026]. Dealroom also states that the company collaborates with Meiji and uses extensive food databases to improve model accuracy, a detail that matters because meal-response prediction depends heavily on food composition data and user context [Dealroom.co]. If that partnership and dataset depth are real in production use, the edge would likely come from better recommendation relevance in Japanese dietary patterns rather than from model architecture alone. That said, the durability of the edge is still unproven from public evidence, because the sources do not establish exclusive data rights, clinical validation outcomes, customer scale, or embedded distribution through providers or payers [PR Times, October 2026] [umin.ac.jp].

The company is more exposed on channels and category breadth than on concept. Public materials support an application and platform thesis, but they do not show that THE PHAGE controls a sensor, a reimbursed care pathway, or a large enterprise sales channel, all of which matter in diabetes management once the product moves beyond engagement into sustained clinical workflow use [Tracxn] [Google Play] [PR Times, October 2026]. That leaves the business vulnerable to better-capitalized incumbents and platform owners that already sit on top of glucose data collection, as well as to adjacent nutrition apps that can copy surface-level meal guidance features faster than a specialist can build distribution. The absence of named commercial customers in the available sources is the clearest public weakness, because it makes it hard to judge whether the company is winning on outcomes, workflow fit, or simply product vision [PR Times, October 2026].

The most plausible 18-month scenario is a split market where the winner is the platform that turns prediction into embedded usage, not the one with the broadest message. Under that setup, THE PHAGE is a winner if its Meiji-linked food data and Glucose Flight workflow produce a noticeably better consumer or clinical experience in Japan, and if the October 2026 Series A first round gives it enough capital to formalize partnerships and evidence generation [Dealroom.co] [PR Times, October 2026]. The loser, if larger diabetes software or device ecosystems tighten their hold on the user interface and data exhaust, is any standalone prediction layer that cannot secure repeat distribution. Public evidence is still too thin to name a verified direct loser by company, which is itself a signal: the category definition around THE PHAGE remains earlier than the financing headline suggests.

Reasoned from indirect evidence -- Core positioning is corroborated across Crunchbase, Tracxn, Genesia Ventures, Dealroom, and PR Times, but the available public record does not name confirmed direct competitors or establish customer-level head-to-head outcomes.

Opportunity

PUBLIC The prize here is not a standalone diabetes app, but a clinically credible prediction layer that could sit between food, behavior, and treatment decisions for a very large and recurring metabolic-health market if THE PHAGE can turn its blood-glucose modeling into a product that institutions trust and distribute at scale [PR Times, October 2026] [Crunchbase] [Genesia Ventures].

The headline opportunity is fairly specific. THE PHAGE is building around postprandial glucose prediction, and the public record points to a proposal-based system rather than a passive logging tool: Crunchbase describes AI technology to predict postprandial blood glucose levels, while Genesia Ventures describes Glucose Flight® as a diabetes support system that analyzes biometric data and generates personalized lifestyle recommendations [Crunchbase] [Genesia Ventures]. That matters because prediction can become a workflow surface for several stakeholders at once, patients trying to manage type 2 diabetes, clinicians looking for more individualized guidance, and commercial partners that care about food-response data. The October 2026 financing also suggests the company has enough institutional backing to pursue that broader platform ambition, with Itochu Technology Ventures leading a ¥570 million Series A first round and follow-on support from Genesia Ventures and Vision Incubate, alongside participation from Tokio Marine & Nichido Fire Insurance and Fukui Capital Partners [PR Times, October 2026].

A reasonable way to think about the upside is through a small number of scale paths rather than one monolithic outcome.

Scenario	What happens	Catalyst	Why it's plausible
Clinical decision-support wedge	Glucose Flight® becomes a recognized support layer for type 2 diabetes management in provider and care-program settings	Validation from medically affiliated leadership and continued financing into product development	Public sources identify Hidetora Kawakami of Chiba University Graduate School of Medicine as involved with the company and participating as CSO, which supports a clinically oriented product posture, though public evidence on deployment is still thin [FIRST CVC]
Food and nutrition intelligence layer	THE PHAGE turns postprandial prediction into an embedded service for food, nutrition, or wellness partners	Expansion of the food-data partnership model	Dealroom states the company collaborates with major firms such as Meiji and uses extensive food databases to improve AI accuracy, which, if accurate, points to a distribution path beyond direct patient acquisition [Dealroom.co]
Insurer and enterprise health channel	The platform is adopted through payer, employer, or health-risk programs rather than consumer channels alone	Strategic support from insurance-linked investors and a B2B operating model	The company is labeled B2B in the structured facts, and Tokio Marine & Nichido Fire Insurance participated in the Series A round, which makes a risk-management or population-health route plausible even if no commercial rollout is yet public [PR Times, October 2026]

The compounding logic is centered on data density. If THE PHAGE can capture repeated meal, biometric, and glycemic-response inputs, its prediction quality could improve with use, and that in turn could make recommendations more useful and retention more defensible; several public descriptions already point in that direction, including Genesia Ventures' account of biometric-data analysis and Dealroom's reference to food-database collaboration [Genesia Ventures] [Dealroom.co]. The more conservative reading is that the flywheel is still mostly conceptual in public evidence, because there are no confirmed usage metrics, customer logos, or outcomes data in the materials reviewed. Even so, the product framing is one of the few in metabolic health where better recommendations plausibly produce better data, and better data plausibly sharpens the core model.

The size of the win is harder to anchor because no confirmed market-sizing source or named public comparable for this exact niche appears in the provided materials. The cleaner framing is conditional: if THE PHAGE becomes a trusted infrastructure layer for postprandial glucose prediction across clinical, nutrition, and insurer channels, it could support venture-scale outcomes well beyond a single-product software business, particularly because the company is positioning around ongoing disease management rather than episodic care [PR Times, October 2026] [Crunchbase] [Genesia Ventures]. In that scenario, not a forecast, the economic value would likely depend less on app monetization and more on whether the company owns a differentiated decision engine tied to proprietary behavioral and metabolic data. That is the form of upside the current evidence points toward, even if the public record does not yet quantify it.

Partially corroborated -- Core company direction is corroborated across Crunchbase, PR Times, and Genesia Ventures, but the section's distribution and compounding assumptions rely partly on single-source descriptions and conditional inference.

Sources

Open sources

1. [Crunchbase] THE PHAGE - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/the-phage

2. [PR Times, October 2026] 株式会社ザ・ファージ、シリーズA 1st ラウンドで総額5.7億円の資金調達を実施 | https://prtimes.jp/main/html/rd/p/000000025.000110505.html

3. [Tracxn] The Phage - 2026 Company Profile, Funding & Competitors | https://tracxn.com/d/companies/the-phage/__EGfU9M4EneTk83X-pkyUstbCXDlcR5gOwZudNfoLfAE

4. [thephage.life, 2026] 株式会社ザ・ファージ／THE PHAGE, Inc. | 食後血糖値の予測AI開発 | https://thephage.life/

5. [Genesia Ventures] Pre-series A investment in THE PHAGE, a provider of personalized blood glucose control solutions | https://www.genesiaventures.com/en/investment-the-phage/

6. [FIRST CVC] The Phage, Inc. | Funding Rounds, Amounts & Investors | https://en.firstcvc.jp/company/thephage.life

7. [ResearchGate] E. Kawakami profile | https://www.researchgate.net/

8. [Google Play] THE PHAGE app listing | https://play.google.com/store/apps/details?id=life.thephage.app

9. [umin.ac.jp] UMIN-CTR Clinical Trial | https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000061770